Mai Capital Management Tricida, Inc. Transaction History

Mai Capital Management

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Jul 19, 2021	SELL	$3.95 - $5.41 $110,023 - $150,690	-27,854 Reduced 47.02%	31,385 $136,000
Q3 2020 Oct 26, 2020	BUY	$8.56 - $26.93 $181,086 - $569,704	21,155 Added 55.55%	59,239 $537,000
Q2 2020 Jul 27, 2020	BUY	$21.21 - $31.55 $231,952 - $345,030	10,936 Added 40.28%	38,084 $1.05 Million
Q1 2020 Apr 16, 2020	BUY	$18.43 - $38.04 $126,485 - $261,068	6,863 Added 33.83%	27,148 $597,000
Q4 2019 Feb 03, 2020	BUY	$29.6 - $43.71 $96,200 - $142,057	3,250 Added 19.08%	20,285 $766,000
Q2 2019 Aug 15, 2019	BUY	$31.16 - $39.46 $186,056 - $235,615	5,971 Added 53.97%	17,035 $672,000
Q1 2019 Apr 29, 2019	BUY	$19.96 - $38.62 $220,837 - $427,291	11,064 New	11,064 $427,000

30K

124K

46.5K

Ticker TCDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,668,900
Market Cap $557K
Description
Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company ...

Get notified when there are updates to the investment portfolio of Mai Capital Management, based on Form 13F filings with the SEC.

Stay updated on Mai Capital Management with notifications on news.